SINGAPORE - United States-based Arcturus Therapeutics, which is jointly developing a Covid-19 vaccine with the Duke-NUS Medical School in Singapore, is preparing to test a single low-dose shot of its messenger RNA vaccine in large trials that will start in the second quarter of the year.
The 5 microgram single-dose regimen will also be a lyophilised, or freeze-dried, version that will be easier and less costly to distribute and store. It will not require the cold chain storage and transport that the usual mRNA vaccine in frozen liquid form needs.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
